Devon Pritchard had spent four years as a Cincinnati firefighter before the depression became something he could no longer outrun on a treadmill or drown at a craft brewery. The 33-year-old had failed sertraline, escitalopram, duloxetine, and a six-month trial of bupropion that gave him insomnia. His psychiatrist at the University of Cincinnati Medical Center suggested he search for TMS centers near me in the Greater Cincinnati area, and Devon found three within twelve miles. He picked the one his Anthem Blue Cross PPO authorised after a 19-day prior auth fight: a NeuroStar provider in Blue Ash run by a board-certified psychiatrist who oversaw two technicians. The first session in November 2025 felt like a woodpecker tapping his forehead. By session 14 his energy crept back. By session 30 he was sleeping six hours, then seven. Devon completed the full 36-session course on a Tuesday morning in February 2026 and walked out into a cold rain feeling something he had not felt in years: bored. Bored, in the best possible way. Three months later he was still working full-time shifts and had not needed a maintenance session.
Transcranial magnetic stimulation has moved from boutique academic treatment to mainstream insurance-covered care over the last decade, and finding the right TMS centers near me in 2026 means understanding which of the three FDA-cleared device families a clinic uses, which indications insurance will cover, and what protocols beyond the standard 6-week course are available. This guide walks through the mechanics of TMS, the device differences, the clinical workflow, insurance reality in 2026, and the accelerated protocols emerging from Stanford and other research centers.
How TMS actually works inside the skull
TMS uses a rapidly alternating magnetic field generated by a coil held against the scalp to induce a small electrical current in the cortical tissue beneath. For depression, the target is the left dorsolateral prefrontal cortex, an area that shows reduced activity in functional imaging of depressed patients. The figure-8 coil concentrates the magnetic field at the intersection of two loops, allowing surgeons of the field to stimulate a roughly 2-3 centimeter region with reasonable precision. No anaesthesia, no sedation, no surgery, no implant. The patient sits in a reclining chair, the coil sits against the head, and pulses fire for about 20 to 40 minutes depending on the protocol.
The therapeutic dose is measured in pulses per session and total pulses per course. Standard 10 Hz protocols deliver 3,000 pulses per session. Theta-burst stimulation, an FDA-cleared shortened protocol, delivers 600 pulses in three minutes by clustering pulses at theta frequency. Deep TMS uses an H-coil that reaches roughly 4 centimeters into the brain rather than the 2-3 centimeters of standard figure-8 coils. Each device family has trade-offs in session length, focality, and FDA-cleared indications.
NeuroStar, BrainsWay, and Magstim: the three device families
NeuroStar Advanced Therapy, made by Neuronetics, is the market leader and the device most commonly found in U.S. clinics. NeuroStar received its first FDA clearance for depression in 2008 and added clearances for adolescent depression (ages 15-21) in 2024 and anxious depression in 2022. Sessions run 19 minutes for the standard protocol and 3 minutes for the theta-burst protocol. The proprietary contact-sensing technology reduces operator error during coil placement.
BrainsWay Deep TMS uses an H-coil that produces a broader, deeper field than standard figure-8 coils. BrainsWay holds FDA clearances for major depressive disorder, OCD, smoking cessation, and anxious depression. The deeper field is hypothesised to reach the cingulate cortex more effectively, which matters for OCD where the surface DLPFC is not the primary target. Sessions run roughly 20 minutes for depression and 18 minutes for OCD with a separate provocation protocol. Treatment-resistant depression specialists often use BrainsWay specifically for patients with comorbid OCD or anxiety.
Magstim Horizon and the related Magstim devices are common in academic medical centers and research-intensive practices. Magstim has FDA clearance for depression and is the device most often used in the SAINT and SNT accelerated protocols developed at Stanford. The platform supports MRI-guided neuronavigation, which a small subset of clinics use to localise the DLPFC target with millimeter precision rather than the standard 5.5 centimeter scalp measurement.
What to look for when comparing TMS centers near me
The clinic should have a board-certified psychiatrist as medical director who personally performs the initial motor threshold determination and the brain mapping at session one. Ongoing daily sessions are typically run by a trained TMS technician under physician supervision; the supervising physician must be on premises or immediately available per most state regulations. Technicians should be certified through the device manufacturer’s training program; ask for verification.
- Board-certified psychiatrist as medical director on site or immediately available
- Manufacturer-certified technicians performing daily sessions
- Documented motor threshold and treatment location protocol at session one
- Clean reports on the FDA’s MAUDE database for the device
- In-network status with at least the major insurers in your market
- Same-device replacement policy if your clinic closes mid-course
Importantly, MRI is not required for standard TMS. Neuronavigation is an optional add-on at academic centers and adds roughly $800 to $1,500 to the course cost. Most insurance plans do not cover the navigation upgrade.
Insurance authorisation: the four-failed-medication rule
Commercial insurance prior authorisation for TMS in 2026 typically requires documentation of failure on at least four adequate antidepressant trials, where adequate means a therapeutic dose for at least six to eight weeks each. Some plans accept three failures plus failure of psychotherapy. Aetna, Anthem, BCBS plans, Cigna, Kaiser, and UnitedHealthcare all cover TMS for major depressive disorder when criteria are met. Coverage for OCD is narrower and typically requires four failed SSRIs at maximum tolerated dose plus an adequate ERP therapy trial.
Medicare Part B covers TMS using HCPCS code 90867 for the initial mapping session and 90868 for subsequent treatment sessions. Medicare Advantage plans follow the underlying Part B coverage but apply their own prior authorisation processes. Medicaid coverage is patchy: roughly 30 state Medicaid programs cover TMS for adults; pediatric and adolescent Medicaid coverage exists in fewer than ten states despite the 2024 NeuroStar clearance for ages 15-21.
The 36-session protocol and what each visit looks like
Standard TMS for depression runs 36 sessions over six to nine weeks. The most common schedule is daily Monday through Friday for six weeks, followed by a six-session taper at three sessions in week seven, two sessions in week eight, and one session in week nine. Some clinics compress the course to 30 sessions or extend to 43 depending on response trajectory. Coordinating treatment with work and family life during a six-week daily course is the practical hurdle most patients underestimate.
Each session takes 20 to 40 minutes in the chair plus 5 to 10 minutes for setup. The patient remains awake, can talk, can listen to music, and drives home immediately afterward. The most common side effect is scalp discomfort at the stimulation site, typically resolving by session 5. Headache occurs in about 30 percent of patients and responds to over-the-counter analgesics. The serious adverse event of concern is seizure, with a documented rate of roughly 1 in 30,000 sessions; clinics screen for seizure risk factors before enrollment.
Cash-pay rates, in-network rates, and the financial reality
The total billed charge for a 36-session TMS course in 2026 ranges from $9,000 to $18,000 cash. In-network insurance reimbursement runs $250 to $400 per session, putting the total contracted amount in the $9,000 to $14,400 range. Patient out-of-pocket cost depends on plan structure: a high-deductible plan may leave the patient owing the first $4,000-$8,000; a traditional PPO with a $50 specialist copay may leave the patient owing roughly $1,800 across the full course. Some clinics offer a self-pay rate of $5,500 to $7,500 for cash-pay patients who do not have insurance coverage.
Maintenance TMS, used for patients who relapse after the index course, is covered by some plans and not others. Medicare currently covers maintenance under medical necessity documentation; most commercial plans cover one re-induction course per 12 months. The FDA-cleared label does not specify a maintenance protocol, which leaves clinicians to design tapering schedules from the published literature.
Accelerated protocols: SAINT, SNT, and the new frontier
The Stanford Neuromodulation Therapy protocol, formerly known as SAINT, compresses the equivalent of 6-9 weeks of standard TMS into five days. Patients receive ten 10-minute theta-burst sessions per day with 50-minute breaks between sessions. The original 2021 trial published by Nolan Williams and colleagues at Stanford reported remission in 78 percent of treatment-resistant patients at week one. The FDA cleared the SAINT protocol in 2022 for treatment-resistant depression. Insurance coverage of SAINT is still developing in 2026; most plans cover it as standard TMS billed across five days, but many SAINT clinics charge cash rates of $15,000 to $25,000.
The trade-off is real: SAINT requires functional MRI-guided neuronavigation in most centers and the schedule demands a five-day commitment with no work or family obligations. For patients with severe depression who cannot wait six to nine weeks, the option matters. For patients who can tolerate the standard course, the longer protocol delivers similar outcomes at a fraction of the price. Some centers are now exploring esketamine combined with TMS; Spravato esketamine clinics sometimes share buildings or referral networks with TMS providers, and the two treatments are not mutually exclusive.
What response and remission actually mean in TMS data
The published response rate for standard TMS in treatment-resistant depression sits at roughly 50-60 percent, with remission rates near 30-35 percent. NeuroStar’s open-label registry of 5,000+ patients reports response in 58 percent and remission in 37 percent at end of acute course. BrainsWay registry data show similar numbers. These rates compare favourably with the STAR*D trial level-three medication switches that produced remission in roughly 14 percent of treatment-resistant patients. The FDA maintains device approval information at fda.gov.
Frequently asked questions
How soon will I feel TMS working?
Most responders notice subtle changes by session 10 to 15. The clearest separation from baseline shows up between session 20 and session 30. Patients who feel nothing by session 25 should discuss alternative protocols or device switches with the prescribing psychiatrist; some patients respond to deep TMS after failing standard TMS or vice versa.
Can I keep taking my antidepressant during TMS?
Yes. The TMS literature was built on patients continuing their oral medications, and stopping medication during TMS introduces a confound the prescriber cannot interpret. The exception is bupropion at high doses, which slightly raises seizure risk; some clinics request a dose reduction during TMS.
Is there an age limit?
NeuroStar received FDA clearance for adolescents aged 15 to 21 in 2024. BrainsWay holds adult-only clearance. There is no upper age limit for FDA-cleared TMS, though clinical trials enrolled few patients over 75. Some Medicare patients in their late seventies and eighties have completed full courses with appropriate cardiac and neurologic screening.
What disqualifies me from TMS?
Ferromagnetic metal in or near the head (cochlear implants, deep brain stimulators, certain aneurysm clips) is a hard contraindication. Active seizure disorder is a relative contraindication; some epileptologists clear stable patients on monotherapy. Pregnancy is not a contraindication for TMS depression treatment, which is one of its advantages over many medications.
Can TMS replace antidepressant medication?
For some patients yes, for others no. The standard practice is to maintain the current medication during the acute course. Patients in sustained remission often taper medication 6 to 12 months after TMS with prescriber guidance. The decision is individual and depends on relapse history, response durability, and side-effect burden of the medication.
The bottom line
Searching for TMS centers near me in 2026 means choosing among three FDA-cleared device platforms, verifying that a board-certified psychiatrist supervises the practice, and budgeting for a daily commute over six to nine weeks. Insurance coverage is broad for treatment-resistant depression and narrower for OCD, anxious depression, and adolescent indications. Cash-pay rates run $5,500 to $7,500 for a typical course, or significantly more for SAINT-style accelerated protocols. For unbiased treatment information, see nimh.nih.gov.
If you are struggling with thoughts of self-harm, call or text 988 to reach the Suicide and Crisis Lifeline, free and confidential 24 hours a day across the United States.
This article is for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Decisions about TMS or any psychiatric treatment should be made with a licensed prescriber familiar with your individual history. Insurance coverage, clinic availability, and pricing change frequently; verify all details with the clinic and your insurance plan before scheduling treatment.